1. Home
  2. PRSO vs APVO Comparison

PRSO vs APVO Comparison

Compare PRSO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.84

Market Cap

7.8M

Sector

Technology

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

N/A

Current Price

$6.58

Market Cap

8.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRSO
APVO
Founded
2008
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
8.3M
IPO Year
2000
2023

Fundamental Metrics

Financial Performance
Metric
PRSO
APVO
Price
$0.84
$6.58
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
293.3K
22.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
86.27
N/A
EPS
N/A
N/A
Revenue
$14,573,000.00
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$35.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.99
N/A
52 Week Low
$0.52
$0.25
52 Week High
$2.37
$13.11

Technical Indicators

Market Signals
Indicator
PRSO
APVO
Relative Strength Index (RSI) 42.80 45.53
Support Level $0.81 $6.12
Resistance Level $0.94 $7.65
Average True Range (ATR) 0.06 0.52
MACD 0.00 -0.06
Stochastic Oscillator 17.12 16.45

Price Performance

Historical Comparison
PRSO
APVO

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: